Jubilant Organosys ties up with US-based Endo Pharmaceuticals

NEW DELHI: Jubilant Organosys through its Bangalore-based subsidiary Jubilant Biosys has entered into a three-year drug discovery & development collaboration with US-based Endo Pharmaceuticals to come out with a portfolio of oncology molecules.

The focus of the tie-up is to develop pre-clinical candidates for joint clinical development, a Jubilant Organosys release said.

Endo will own the compounds developed under the partnership and will also be responsible for its worldwide commercialisation. Delhi-based Jubilant Organosys will receive research funding and success-based milestone payments from the American firm, besides royalties on successful commercialisation, the company statement added.

Jubilant Organosys CMD Shyam Bhartia and Co-CMD Hari Bhartia in a joint statement said: ���We anticipate significant rewards on successful development of compounds and its subsequent commercialisation.���

While funding for research is expected to kick in from this quarter onwards, milestone linked payments for such research projects usually takes 6-9 months, subject to meeting the targets.